All In MedTech

Device type · CEP

Radioimmunoassay, Luteinizing Hormone

FDA groups similar devices under a three-letter product code. This page gathers what FDA's public data says about CEP: how it is classified, what has been cleared or approved, and what has been reported and recalled.

Last checked: Nov 19, 2026Source: openFDAMethods & limitations

Product code

CEP

Clinical Chemistry

Device class

Class I

FDA decisions since 2015

0

510(k), De Novo and PMA

Adverse event reports

0

Received Nov 1, 2025 to Nov 19, 2026

How FDA classifies it

Device type
Radioimmunoassay, Luteinizing Hormone
Product code
CEP
Device class
Class I
Review panel
Clinical Chemistry
Regulation
21 CFR 862.1485

Latest FDA decisions

All decisions for CEP

No 510(k), De Novo or PMA decisions for this product code since 2015.

Reports received

0

Received Nov 1, 2025 to Nov 19, 2026

Malfunction reports

0

Injury reports

0

Death reports

0

Adverse event reports received per month

By the date FDA received each report, stacked by event type. The newest month is incomplete.

Open in the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 230100
Jan 240000
Feb 240000
Mar 240000
Apr 240000
May 240000
Jun 240000
Jul 240000
Aug 240000
Sep 240000
Oct 240000
Nov 240000
Dec 240000
Jan 250000
Feb 250000
Mar 250000
Apr 250000
May 250000
Jun 250000
Jul 250000
Aug 250000
Sep 250000
Oct 250000
Nov 250000
Dec 250000
Jan 260000
Feb 260000
Mar 260000
Apr 260000
May 260000
Jun 260000
Jul 260000
Aug 260000
Sep 260000
Oct 260000
Nov 260000

Manufacturers named most often

Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.

No manufacturers to rank.

Device problems as coded

Last 12 months. FDA's terms. A report can carry several.

No device problems coded.

Patient problems as coded

Last 12 months. FDA's terms. A report can carry several.

No patient problems coded.

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

  • Biomerieux Inc

    Z-0865-2023 · Started Nov 9, 2022 · Posted by FDA Jan 4, 2023

    Reason given: As the temperature and time out of range was exceeded, product performances cannot be guaranteed

    Cause as FDA categorized it: Storage

  • Ortho-Clinical Diagnostics, Inc

    Z-1113-2022 · Started Mar 25, 2022

    Reason given: Falsely high or delayed patient and QC results may occur due to low end imprecision. VITROS Immunodiagnostic Products FSH, LH and Prol Reagents Low End Imprecision. Low-level quality control (QC) and patient samples at the low end of the Measuring (Reportable) Range when using VITROS FSH, LH and Prol Reagent....

    Cause as FDA categorized it: Device Design

  • VIDAS LH, REF 30406-01Open, Classified

    bioMerieux, Inc.

    Z-0433-2022 · Started Sep 22, 2021

    Reason given: bioMerieux has been receiving an increasing number of complaints linked to a VIDAS substrate error. It prevents the test from being run, therefore leads to potential delayed results as the user must run another test.

    Cause as FDA categorized it: Nonconforming Material/Component

3 more recall records with a free account

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.